The feds scored a few cheap points when they ordered the suspension of a new trial on the dangerous diabetes drug Avandia.

But don't kid yourself, this isn't about protecting the human guinea pigs that would have been endangered by that study -- it's window dressing, because no one was signing up for it anyway.

They quickly put up those curtains because they needed to draw attention from the real story as quickly as possible -- and that's the story of one of the most bizarre decisions in the history of the FDA.

And you know I don't say that lightly.

Despite overwhelming evidence that this med increases the risk of heart attacks, a federal panel voted 20-12 to keep it on the market.

How could that happen, you ask? Easy -- the panel had more conflicts and drug money than a South American banana republic.

Days after the panel met, it came out that endocrinologist David Capuzzi had been paid $14,000 by GlaxoSmithKline, makers of Avandia, for work he's done for the company. He even served on an Avandia advisory panel -- something he claims he doesn't remember.

He was one of just three panelists to vote for keeping the drug on the market with no new warnings or restrictions.

"I don't care what the controlled clinical trials show," he said, according to the New York Times. No, really -- he actually said that.

"Well, I do but I don't think it's knock down complete," he quickly added, probably once he realized he sounded like a complete nincompoop.

Too late, pal.

This kind of funny business is nothing new. In fact, just about all the "researchers" and "experts" who favor Avandia have been taking Big Pharma dollars. One recent analysis found that nearly every pro-Avandia researcher who has defended it since 2007 had financial ties to the company.

And if that's not enough, it turned out that another panelist had financial ties to the maker of an Avandia rival. Naturally, he voted against the drug.

The whole thing's a charade.

But this doesn't even scratch the surface on the massive coverup surrounding this dangerous drug. To get the full scoop, keep an eye out for the September issue of the Douglass Report. If you're not a subscriber yet, click here to sign up.